Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 7/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | KIF15 | Q9NS87 | 1/20 | 1.00 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.66 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw406108X SCHEMBL5772848 | 1.00 | RAF1 (1.00) | RAF1ULK1KIF15TLK2PLK4 | |
| Gw406108X SCHEMBL30510961 | 1.00 | RAF1 (1.00) | RAF1ULK1KIF15TLK2PLK4 | |
| SCHEMBL5777929 | 0.88 | RAF1 (0.78) | RAF1ULK1KIF15TLK2PLK4 | |
| SCHEMBL5777933 | 0.88 | RAF1 (0.78) | RAF1ULK1KIF15TLK2PLK4 | |
| SCHEMBL5080462 | 0.84 | RAF1 (0.76) | RAF1ULK1KIF15TLK2PLK4 | |
| SCHEMBL1395408 | 0.84 | RAF1 (0.76) | RAF1ULK1KIF15TLK2PLK4 | |
| SCHEMBL7982366 | 0.81 | RAF1 (0.69) | RAF1ULK1KIF15TLK2PLK4 | |
| SCHEMBL5773594 | 0.80 | RAF1 (0.67) | RAF1ULK1KIF15TLK2PLK4 | |
| SCHEMBL5773597 | 0.80 | RAF1 (0.67) | RAF1ULK1KIF15TLK2PLK4 | |
| SCHEMBL1394705 | 0.80 | RAF1 (0.67) | RAF1ULK1KIF15TLK2PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12186318-B2 | Pharmaceutical composition for preventing or treating cancer comprising KSP inhibitor and mitosis inhibitor | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-01-07 | — | — | US | disclosed |
| US-20240342179-A1 | TREATMENT OF CANCERS OR NEOPLASMS BY INHIBITING KIF15 | UNIVERSITY OF KANSAS | 2024-10-17 | — | — | US | disclosed |
| EP-1975620-A2 | Three hybrid assay system | GPC Biotech AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| EP-1003721-B1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LTD (GB) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342179-A1 | TREATMENT OF CANCERS OR NEOPLASMS BY INHIBITING KIF15 | KIF15, KIF11, KIF2C | RAF1 572/4885ULK1 2099/4885KIF15 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.